<SEC-DOCUMENT>0001193125-17-206418.txt : 20170804
<SEC-HEADER>0001193125-17-206418.hdr.sgml : 20170804
<ACCEPTANCE-DATETIME>20170619070232
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-17-206418
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20170619

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cerulean Pharma Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-769-9145

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g320129snap0010.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g320129snap0011.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;19, 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Via
EDGAR Submission </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and
Insurance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Suzanne Hayes </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cerulean Pharma Inc. </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Amendment No.&nbsp;2 to Preliminary Proxy Statement on Schedule 14A </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Filed June&nbsp;13, 2017 </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>File No.&nbsp;001-36395 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerulean Pharma Inc. (the &#147;Company&#148;) has filed today with the Securities and Exchange Commission (the &#147;Commission&#148;) a Definitive Proxy
Statement on Schedule 14A (the &#147;Definitive Proxy Statement&#148;). This letter, together with the Definitive Proxy Statement, sets forth the Company&#146;s responses to the comments contained in a letter from the staff of the Commission (the
&#147;Staff&#148;), dated June&nbsp;15, 2017 (the &#147;Comment Letter&#148;), relating to the Company&#146;s Preliminary Proxy Statement on Schedule 14A, initially filed with the Commission on April&nbsp;17, 2017 (File No.&nbsp;001-36395), and
amended by Amendment No.&nbsp;1 to the Preliminary Proxy Statement filed on May&nbsp;26, 2017 and Amendment No.&nbsp;2 to Preliminary Proxy Statement filed on June&nbsp;13, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The responses set forth herein are based upon information provided to Wilmer Cutler Pickering Hale and Dorr LLP by the Company. The responses are keyed to the
numbering of the comments in the Comment Letter and to the headings used in the Comment Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms used but not otherwise defined in this letter have
the respective meanings ascribed to such terms in the Definitive Proxy Statement. Page references in the responses set forth below are to pages in the clean copy of the Definitive Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the Company, we advise you as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wilmer Cutler Pickering Hale and Dorr <SMALL>LLP</SMALL>, 60 State
Street, Boston, Massachusetts 02109 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Beijing&nbsp;&nbsp;&nbsp;&nbsp;Berlin&nbsp;&nbsp;&nbsp;&nbsp;Boston&nbsp;&nbsp;&nbsp;&nbsp;Brussels&nbsp;&nbsp;&nbsp;&nbsp;Denver&nbsp;&nbsp;
&nbsp;&nbsp;Frankfurt&nbsp;&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;Los&nbsp;Angeles&nbsp;&nbsp;&nbsp;&nbsp;New&nbsp;York&nbsp;&nbsp;&nbsp;&nbsp;Palo&nbsp;Alto&nbsp;&nbsp;&nbsp;&nbsp;Washington </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and
Insurance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;19, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Opinion of Cerulean&#146;s Financial Advisor, page 116 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>We note your response to prior comment 4 and your revised disclosure that the stage of development of Ovaprene is analogous to Phase 2 for a candidate that is regulated as a drug. Please explain to us how these two
stages are analogous, or, in the alternative, please remove this statement</I>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response:</B> In response to the
Staff&#146;s comment, the Company has revised the disclosure on pages 123 through 126 of the Definitive Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Selected Historical and
Unaudited Pro Forma Combined Financial Information </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Comparative Historical and Unaudited Pro Forma Per Share Data, page 32 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please explain the events that occurred to change the Dare Pro Forma equivalent basic and diluted net loss per share for the year ended December&nbsp;31, 2016 from ($0.04) in prior filings to ($0.55) and provide your
calculation</I>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company advises the Staff that it had incorrectly calculated the pro forma equivalent
basic and diluted net loss per share and the pro forma equivalent book value per share of Dar&eacute; Bioscience, Inc.&#146;s common stock for each of the year ended December&nbsp;31, 2016 and the three months ended March&nbsp;31, 2017. For purposes
of this calculation the Company has assumed that holders of Dar&eacute;&#146;s equity securities receive 60% of the outstanding Cerulean equity securities on a fully diluted basis, which is approximately the midpoint of the number of shares the
holders of Dar&eacute;&#146;s equity securities may receive in the Dar&eacute; Transaction. This ownership percentage results in a Dar&eacute; exchange ratio of 2.893319797. Applying this exchange ratio to Dar&eacute;&#146;s Historical Per Common
Share Data results in the following Pro Forma Equivalent Common Share Data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DAR&Eacute; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of or for<BR>the Year<BR>Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;or&nbsp;for<BR>the&nbsp;Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Historical Per Ordinary Share Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma Equivalent Common Share
Data:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends declared per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Assumes holders of Dar&eacute; equity securities receive 60% of the outstanding Cerulean equity securities on a fully-diluted basis. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has included the above revised table and footnote on page 32 of the Definitive Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and
Insurance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;19, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any further questions or comments, or if you require any additional
information, please contact the undersigned by telephone at (617)&nbsp;526-6982 or facsimile at (617)&nbsp;526-5000. Thank you for your assistance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Lia Der Marderosian</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lia Der Marderosian</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top">Christopher D.T. Guiffre </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cerulean Pharma Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top">Chris Edwards, United States Securities and Exchange Commission </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g320129snap0010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320129snap0010.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( !@ >0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /6O%OBBX\*I97!T^.>QGN$MY9VN#'Y!8X#,-A^7WS^% $$_
MC"XL_%T^@WFG06ZK9O>0W3W1V2(O48V<$=3UP!GF@ /BK5DT[2+F30HEGU%B
M1;_:V+1)L+[FQ'DX Y '4@<YX -"/QAH,FAOK27X;3$;:UR(W* _7'3/&>F:
M -!=4M&TH:FKN;0IY@<1MDKZ[<9QWZ=.: #2]5L=;TZ+4--N4N;27.R1.AP2
M#^H- %*/Q5HLMI?7<5Z)+:P8I<RI&[+&1]X$@=NIQT'/2@!UEXGTC49;>.UN
MB[7"%X<Q.HD4#.5) !XYXH K1>-_#<S[%U6)<3?9RTBLBB3^X2P #>QYH AU
M'Q/>6/C33/#ZZ9%(M^CR)<&Y*[0@RV5V'GTY_*@!WB;Q-=>']0TBVBTV*Z34
M[E;5':Y,>QSD\C8>,#U_"@#8N-3L[*YL[6[N(XKB\8I#&3]]@,D#\!0!!J'B
M#3-*O[6QO+DQ7-T<0)Y;,9#Z+@<GVH =JNNZ;H:P-J-QY"SN(XR8V8,YZ*,
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M_!W-:CS%.[9C&. -V>,].E '=>*+2:?XH>$+>SOY+1Q:7.V=%5V "CLP(.:
M*_C#3M0LM?\ !K7FN7&H(VL1@1RPQ(%.#SE%'^30!0^(TFHW=Y=Z[8V$\R>'
M)HFMYT=!&K+\\^06W$$,B\ _</O0!N^);R'4/%?P\OK=MT%Q/++&WJK0Y'Z&
M@";XH.QTS1$@:,SKK5H55CP"6.,XYQD?I0!TFEO=Q7=R-8:S2\GEVVWE$ R1
M*BG S\QPS.>>F3V- &O0 4 8]MX8TJUU/5]02W!GU8*MUNY5@J[< =LCKZT
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7Y;N(%8Y)[J68H""#C>QQU/2@#6H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g320129snap0011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320129snap0011.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "P 6 ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z (([RWENY[2.96G@"M(@ZH&SMS]<&@"JVNZ:BW+O=!$M
M@QD=E8+\IVG!(PV#P<9YXH GEU&VAO8;21G2:9MD>8VVL=I; ;&,X!/7M0!'
M)J]E$UP'D<?9SB0B)R >. <8)^8<#GF@"-->TUWB1;@EI3M \MLJ=Y3#<?)\
MP*_-CD$=J )9M7L;:[-M-<!) NYLJ=JC!/+8P.%)P3VH @_X2+2MBL;DKDD$
M-$X9<;22P(RHPZG)P/F'J* +-KJ=G>7$UO;S!Y820XVD="5.">N"I!QT(Q0
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1 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
